MRX-2843 and Osimertinib for the Treatment of Advanced EGFR Mutant Non-small Cell Lung Cancer

NCT04762199 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

69

Enrollment

OTHER

Sponsor class

Conditions

Advanced Lung Non-Small Cell Carcinoma
Metastatic Lung Non-Small Cell Carcinoma
Stage IV Lung Cancer AJCC v8
Stage IVA Lung Cancer AJCC v8
Stage IVB Lung Cancer AJCC v8

Interventions

DRUG: Flt3/MerTK Inhibitor MRX-2843
DRUG: Osimertinib

Sponsor

Emory University

Collaborators

[object Object]